ClinicalTrials.gg
CompletedNCT06023030Updated Nov 12, 2026

An Observational Study to Assess Change in Disease Activity and Adverse Events in Adolescent and Adult Participants With Moderate to Severe Active Crohn's Disease (CD) in Japan

An observational study in Crohn's Disease, sponsored by AbbVie. Completed at 104 sites in Japan. Open to participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by AbbVie · Observational

How we know

Updated Nov 12, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
253
Ages
15 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 55 studies in Crohn Disease by AbbVie — 6 open to participants now, 14 under way, 6 of them phase 3. Crohn Disease · AbbVie.

Enrollment
13th of 26
253 · median 252
Started
2023
with 4 others
Observational
26 of 55
3 open now
Registered
45th of 55
by date

Among the 55 studies in Crohn Disease by AbbVie, this one is the 13th largest by enrollment of the 26 observational ones that give a count, is one of 5 that started in 2023, is one of 26 observational ones, and was the 45th registered.

Crohn Disease

1,995 studies on the registry are indexed under Crohn Disease; 477 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

6 of the 55 studies in Crohn Disease by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 155 (44%) set no upper age limit and 143 (41%) stop at 75 or younger; 94 take children under 18; 56 take healthy volunteers.

This study: 15 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Crohn Disease by AbbVie, or all of them as a file.
02

Study summary

Crohn's disease (CD) is an incurable chronic inflammatory disorder of the gastrointestinal tract. This study will assess how safe and effective upadacitinib is in treating moderately to severely active CD in real world. Adverse events and change in disease activity will be assessed.

Upadacitinib is a drug approved for the treatment of CD. All study participants will receive upadacitinib as prescribed by their study doctor in accordance with approved local label. Approximately 240 participants will be enrolled in Japan.

Participants will receive upadacitinib as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed for up to 64 weeks.

There is expected to be no additional burden for participants in this trial. Study visits may be conducted on-site or virtually as per standard of care.

03

Conditions studied

  • Crohn's Disease

Browse trials for

Keywords

  • Crohn's disease
  • Upadacitinib
04

Who can participate

Ages eligible
15 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Children and Adult participants with Crohn's disease (CD) in Japan.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with moderately to severely active Crohn's disease (CD).
  • Has been prescribed upadacitinib for CD as per most current local approved label after its approval for CD in Japan.
  • Within 14 days from the commencement of upadacitinib induction treatment for CD at the participating institution.

Exclusion criteria

Exclusion Criteria:

  • Currently participating in another interventional clinical research.
  • Participants for whom upadacitinib is .
  • Has been treated with upadacitinib for CD before and continue treatment with upadacitinib for CD at the participation to this study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
253 participants (actual)

Groups and cohorts

  • Upadacitinib

    Participants will receive upadacitinib as prescribed by their physician according to local label.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants with Drug Related Serious Infections

    Pecentage of participants with serious infections.

    Time frame: Up to 64 Weeks

07

Study locations

104 sites

Showing the first 100 of 104 sites. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2023 to primary completion in Sep 2026, 37 months.

Of 73 industry-sponsored observational studies under Crohn Disease, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 60. This study's 37 months is close to that.

Counting every sponsor, half of 305 studies reached it within 41 months; a quarter within 29 and three quarters within 88.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Nov 2026 → Sep 2026 and completion May 2027 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2023
First posted
Sep 5, 2023
StartActual
Jul 28, 2023
Primary completionActual
Sep 11, 2026was Nov 2026
CompletionActual
Sep 11, 2026was May 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 12, 2026
Primary completion
Nov 2026→Sep 11, 2026 (actual)
Nov 12, 2026
Study completion
May 2027→Sep 11, 2026 (actual)
Nov 12, 2026
Enrollment
240 (estimated)→253 (actual)
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Recruiting→Completed
    Primary completion Nov 2026→Sep 11, 2026 (now actual)
    Study completion May 2027→Sep 11, 2026 (now actual)
    Enrollment 240 (estimated)→253 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06023030
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Sep 5, 2023
Start date
Jul 28, 2023
Primary completion
Sep 11, 2026
Completion
Sep 11, 2026
Last update
Nov 12, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion